Bio-rad Laboratories Stock News

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 publicly-traded companies in the Analytical instruments industry, but how does it weigh in compared to its peers? We will compare Bio-Rad Laboratories to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, analyst recommendations, risk and earnings. Analyst Ratings This is a summary []

Bio-Rad Laboratories, Inc. (NYSE:BIO.B)s share price reached a new 52-week high on Tuesday . The company traded as high as $752.95 and last traded at $752.95, with a volume of 7 shares trading hands. The stock had previously closed at $752.95. The firm has a market cap of $22.53 billion, a P/E ratio of 3.42 []

Related Stocks: IWM , MSFT , FIS , ROST , DHHCU , VTWO , NGMS , OPEN , FRSH , FRSH , DALS , WIX , ATUS , BIO , MARA , CELC , GOAC.U ,

Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Annette Tumolo sold 1,546 shares of the companys stock in a transaction dated Thursday, November 11th. The stock was sold at an average price of $749.00, for a total transaction of $1,157,954.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through []

Key Companies Covered in the Liquid Biopsy Market Research Report Are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Illumina, Inc., Inivata Limited, Agena Bioscience, Inc., Thermo Fisher Scientific, Guardant Health, Inc., and other key market players. Key Companies Covered in the Liquid Biopsy Market Research Report Are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Illumina, Inc., Inivata Limited, Agena Bioscience, Inc., Thermo Fisher Scientific, Guardant Health, Inc., and other key market players.

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 public companies in the Analytical instruments industry, but how does it contrast to its rivals? We will compare Bio-Rad Laboratories to related companies based on the strength of its earnings, risk, valuation, institutional ownership, dividends, profitability and analyst recommendations. Profitability This table compares Bio-Rad Laboratories and its []

Bio-Rad Laboratories (NYSE: BIO.B) is one of 42 public companies in the Analytical instruments industry, but how does it weigh in compared to its competitors? We will compare Bio-Rad Laboratories to similar businesses based on the strength of its dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability. Analyst Recommendations This is a breakdown []

Strength in the Life Science and Clinical Diagnostics segments drove Bio-Rad's (BIO) revenues in the third quarter.

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q3 2021 Results - Earnings Call Transcript

Beating the market is hard, but it can be made easier by using the right set of tools. Here are the metrics to analyze penny stocks.

We believe that there are other stocks that are currently better valued than eBay's stock. EBAY's current price-to-operating income ratio (P/EBIT) of 16.7x is higher than levels of 13.3x for PerkinElm

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Investors are optimistic about Bio-Rad (BIO) on solid international market performance and raised 2021 guidance.

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the thi

Bio Rad (BIO) is witnessing strong growth in the biopharma market, riding on the Droplet Digital PCR platform.